Fourth Manhattan Alzheimer's Disease Conference on May 27 Sponsored by Nymox Will Feature World...

Business Editors/Health/Medical Writers

MAYWOOD, N.J.--(BUSINESS WIRE)--April 16, 2003

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that it will sponsor the Fourth Manhattan Alzheimer's Disease Conference at the Waldorf Astoria Hotel in New York City

Amongst the distinguished speakers there will be world experts on existing drug treatments for Alzheimer's Disease (AD), future drugs for AD, novel approaches to therapy of AD, molecular diagnostics of AD, and molecular biology of AD. In addition there will be other important topics such as managed care, ethical considerations, national support organizations, and talks from renowned authors and specialists. The session chairmen for the meeting will be Leslie Iversen Ph.D. of Kings College London, and Paul Averback M.D. of Nymox.

"This promises to be the best Manhattan Alzheimer's Conference to date." said Dr. Michael Munzar, Medical Director Nymox and one of the conference organizers. The field is moving in interesting directions. We are impressed by the extremely high quality of this year's program including both exciting new findings and novel approaches to this devastating disease."

Alzheimer's disease is a multi-faceted illness, not only from a medical or scientific standpoint but also in terms of important social, economic, legal and ethical issues it raises and the challenges it poses to the healthcare industry and society at large. While there are effective treatments, the absence of available therapeutics aimed at the causes of the disease highlight the need for new and different approaches to this tragic neurodegenerative illness.

Nymox's research and development programs concentrate on novel approaches to therapeutics and diagnostics with a specific focus on the diagnosis and treatment of Alzheimer's disease. Nymox offers AlzheimAlert(TM), a unique urine test designed to aid physicians in the diagnosis of Alzheimer's disease. Nymox has several major proprietary drug development programs with candidate drugs for Alzheimer's disease. One major drug discovery platform targets neural thread protein, the brain protein detected by Nymox's AlzheimAlert(TM) test and implicated in the Alzheimer's disease process. Another targets spherons, tiny balls of densely packed protein found scattered in human brain cells from an early age. Nymox also holds the patent rights for the use of statin drugs for the prevention or treatment of Alzheimer's disease. Statins are widely available drugs for the reduction of cholesterol, representing a $14 billion market worldwide. There is a body of recent scientific publications and studies linking cholesterol to Alzheimer's disease and certain aspects of the Alzheimer's disease process and showing a significantly reduced incidence of Alzheimer's disease for patients taking statin drugs to lower their cholesterol.

Nymox's AlzheimAlert(TM) offers an aid to physicians in the diagnosis of Alzheimer's disease. The test uses first-morning urine samples to detect levels of a brain protein called neural thread protein or NTP known to be elevated in the patients with Alzheimer's disease. The development of the AlzheimAlert(TM) urine test has been extensively reported in the peer-reviewed scientific and medical literature. Recent publications include Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Cellular and Molecular Life Sciences (2001; 58: 844-849); Journal of Alzheimer's Disease (2001; 3: 345-353); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104). The AlzheimAlert(TM) urine test is available to physicians through Nymox's certified Clinical Reference Laboratory in Maywood, New Jersey at a cost of $295.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.